Citicoline for treating people with acute ischemic stroke

Martí‐Carvajal, Arturo J; Valli, Claudia; Solà, Iván; Martí‐Fàbregas, Joan; Cosp, Xavier Bonfill

doi:10.1002/14651858.cd013066

Cited by 15 publications

(21 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is experimental evidence that the anti-apoptotic effect of citicoline is realized by mitochondrial mechanisms, as well as by the increased expression of anti-apoptotic protein Bcl-2 (Gandolfi et al 2020;Kamel et al 2020;Nashine and Kenney 2020). In addition, the ability of citicoline to activate neuroregeneration also contributes to a quicker improvenent of morphofunctional disorders in TBI (Gandolfi et al 2020;Martí-Carvajal et al 2020).…”

Section: Discussionmentioning

confidence: 99%

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

Antsiferov¹,

Cherevatenko²,

Корокин³

et al. 2021

RRP

View full text Add to dashboard Cite

Introduction: EP-11-1 (UEHLERALNSS) is a short-chain erythropoietin derivative without have erythropoietic activity. It was created by modifying a peptide mimicking the spatial structure of the erythropoietin a-helix B pHBSP. One of the promising directions of its administration is the correction of morphofunctional disorders that occur in traumatic brain injury (TBI). Materials and methods: The study was performed in 160 male Wistar rats, weighing 180–200 g.TBI was simulated using the drop-weight method. To assess the emerging morphofunctional disorders and a degree of their correction, we used the severity of neurological deficit, indicators of locomotor activity and exploration, a marker of brain injury S100B and morphological examination. Results and discussion: The combined administration of a new EPOR/CD131 heteroreceptor agonist EP-11-1 with citicoline and trimetazidine led to a more pronounced correction of the neurological deficit when compared not only to the group of the ”untreated” animals, but also to the groups of animals to which these drugs had been administered as monotherapy (p < 0.05). The same tendency was also observed in the study of locomotor activity and exploration. A biochemical study showed that the administration of all three combinations led to a statistically significant (p < 0.05) decrease in the S-100B concentration compared not only to the group of “untreated” animals, but also to the groups of animals to which these drugs had been administered as a monotherapy. Conclusion: The results of the conducted experiments prove the most pronounced positive dynamics in the combined administration of the new EPOR/CD131 heteroreceptor agonist EP-11-1with citicoline and trimetazidine.

show abstract

Section: Discussionmentioning

confidence: 99%

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

Antsiferov¹,

Cherevatenko²,

Корокин³

et al. 2021

RRP

View full text Add to dashboard Cite

show abstract

“…In addition, the authors reported that several studies included in the review had a high risk of bias, having been sponsored by pharmaceutical companies. Author neutrality is also scientifically questionable since some of the authors of the studies were receiving honoraria and consultation fees from drug firms 17 . A meta‐analysis of clinical trials on Sodium Ozagrel in treatment of acute ischemic stroke showed its effectiveness in improving short‐term impairment, but large scale, high quality studies are needed to prove beneficial effects on long‐term disability 18 .…”

Section: Problems In Bench To Bedside Translationmentioning

confidence: 99%

Preclinical animal studies in ischemic stroke: Challenges and some solutions

Narayan

Cherian

Phaniti

et al. 2021

Anim Models and Exp Med

View full text Add to dashboard Cite

Despite the impressive efficacies demonstrated in preclinical research, hundreds of potentially neuroprotective drugs have failed to provide effective neuroprotection for ischemic stroke in human clinical trials. Lack of a powerful animal model for human ischemic stroke could be a major reason for the failure to develop successful neuroprotective drugs for ischemic stroke. This review recapitulates the available cerebral ischemia animal models, provides an anatomical comparison of the circle of Willis of each species, and describes the functional assessment tests used in these ischemic stroke models. The distinct differences between human ischemic stroke and experimental stroke in available animal models is explored. Innovative animal models more closely resembling human strokes, better techniques in functional outcome assessment and better experimental designs generating clearer and stronger evidence may help realise the development of truly neuroprotective drugs that will benefit human ischemic stroke patients. This may involve use of newer molecules or revisiting earlier studies with new experimental designs. Translation of any resultant successes may then be tested in human clinical trials with greater confidence and optimism.

show abstract

“…No difference in (serious) adverse events were found in all above mentioned studies. "A comprehensive review and meta-analysis concerning Citicoline can be found elsewhere [87]".…”

Section: Compoundsmentioning

confidence: 99%

Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review

Mulder

Bavel

Vries

et al. 2021

Fluids Barriers CNS

View full text Add to dashboard Cite

With the introduction of endovascular thrombectomy (EVT), a new era for treatment of acute ischemic stroke (AIS) has arrived. However, despite the much larger recanalization rate as compared to thrombolysis alone, final outcome remains far from ideal. This raises the question if some of the previously tested neuroprotective drugs warrant re-evaluation, since these compounds were all tested in studies where large-vessel recanalization was rarely achieved in the acute phase. This review provides an overview of compounds tested in clinical AIS trials and gives insight into which of these drugs warrant a re-evaluation as an add-on therapy for AIS in the era of EVT. A literature search was performed using the search terms “ischemic stroke brain” in title/abstract, and additional filters. After exclusion of papers using pre-defined selection criteria, a total of 89 trials were eligible for review which reported on 56 unique compounds. Trial compounds were divided into 6 categories based on their perceived mode of action: systemic haemodynamics, excitotoxicity, neuro-inflammation, blood–brain barrier and vasogenic edema, oxidative and nitrosative stress, neurogenesis/-regeneration and -recovery. Main trial outcomes and safety issues are summarized and promising compounds for re-evaluation are highlighted. Looking at group effect, drugs intervening with oxidative and nitrosative stress and neurogenesis/-regeneration and -recovery appear to have a favourable safety profile and show the most promising results regarding efficacy. Finally, possible theories behind individual and group effects are discussed and recommendation for promising treatment strategies are described.

show abstract

Citicoline for treating people with acute ischemic stroke

Cited by 15 publications

References 61 publications

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

Preclinical animal studies in ischemic stroke: Challenges and some solutions

Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review

Contact Info

Product

Resources

About